Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mar

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

FDA Approves Teclistamab and Daratumumab For Relapsed or Refractory Multiple Myeloma

Medical Societies and More Respond to HHS RFI on AI Use in Clinical Care

Accuracy of Molecular Inference–Based AI Model for CNS Tumor Diagnosis

Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer

Short-Term Vaginal Estrogen Therapy Does Not Increase Risks of Endometrial Cancer Recurrence